Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bayer AG | 445 |
| 2 | BASF SE | 342 |
| 3 | Bayer CropScience AG | 171 |
| 4 | Syngenta Crop Protection AG Switzerland | 147 |
| 5 | Corteva Agriscience LLC | 123 |
| 6 | Sumitomo Chemical Co Ltd | 104 |
| 7 | Intervet International BV | 92 |
| 8 | Elanco Animal Health GmbH | 72 |
| 9 | Boehringer Ingelheim Animal Health USA Inc | 42 |
| 10 | Zoetis Services LLC | 41 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A01N | Preservation of bodies; biocides; pest repellents | 2,065 |
| 2 | C07D | Heterocyclic compounds | 1,613 |
| 3 | A01P | Biocidal activity of chemical compounds | 1,023 |
| 4 | A61P | Therapeutic activity (drug indications) | 764 |
| 5 | A61K | Medicinal preparations | 571 |
| 6 | C07C | Acyclic and carbocyclic compounds | 253 |
| 7 | Y02A | Climate change adaptation | 229 |
| 8 | A01C | 109 | |
| 9 | C07F | Organometallic compounds | 103 |
| 10 | C05G | 91 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Methods for treating demodex blepharitis using lotilaner formulations | 2023 | Tarsus Pharmaceuticals Inc | 3 |
| Methods for treating ocular Demodex using lotilaner formulations | 2023 | Tarsus Pharmaceuticals Inc | 3 |
| Ophthalmic compositions for treating ocular Demodex using lotilaner formulations | 2023 | Tarsus Pharmaceuticals Inc | 1 |
| PROCESS FOR LOTILANER INTERMEDIATE | 2022 | Elanco Shanghai Animal Health Co Ltd | 0 |
| Lotilaner and salts thereof | 2017 | ELANCO TIERGESUNDHEIT AG | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Dermatology and Skin Diseases | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Scott Wiseman | Elanco (United States) | 11 |
| 2 | Daniel E. Snyder | Danieli (Italy) | 6 |
| 3 | Elizabeth Yeu | Virginia Eye Consultants | 5 |
| 4 | Lisa Young | Elanco (United States) | 5 |
| 5 | Mark Holdbrook | Taro Pharmaceuticals (United States) | 5 |
| 6 | Stephanie N. Baba | Taro Pharmaceuticals (United States) | 5 |
| 7 | Craig R. Reinemeyer | East Tennessee Clinical Research | 4 |
| 8 | Claudia Corredor-Ortega | Asociacion Para Evitar la Ceguera en México Hospital Dr. Luis Sánchez Bulnes | 3 |
| 9 | Daniela Karadzovska | Australasia Paediatric Endocrine Group | 3 |
| 10 | Elizabeth Crawley | Elanco (United States) | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1) | 2022 | 51 | Ocular Surface and Contact Lens |
| Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis | 2023 | 47 | Ocular Surface and Contact Lens |
| Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: A randomized, controlled, double-masked clinical trial | 2021 | 32 | Olfactory and Sensory Function Studies |
| A randomized, controlled field study to assess the efficacy and safety of lotilaner flavored chewable tablets (Credelio™ CAT) in eliminating fleas in client-owned cats in the USA | 2021 | 29 | Dermatology and Skin Diseases |
| Lotilaner Ophthalmic Solution 0.25%: First Approval | 2023 | 19 | Acne and Rosacea Treatments and Effects |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Lotilaner?
What are the primary commercial names for Lotilaner?
Which organizations hold the most patents related to Lotilaner?
What are the main clinical applications of Lotilaner based on recent research?
How has patent activity for Lotilaner evolved in recent years?